LAS VEGAS, November 1, 2022 /PRNewswire/ — The VIVA Foundation, a nonprofit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results of the second of three late-breaking clinical trials sessions at the VIVA22 conference known. held at the Wynn Las Vegas.
VIVA (Vascular InterVentional Advances) is an annual vascular education symposium that brings together a global, multispecialty faculty to present a variety of lectures and live case presentations from clinical centers around the world. Attendees include interventional cardiologists, interventional radiologists, vascular surgeons and endovascular medicine specialists. Below are summaries of this afternoon’s 6 hot topic clinical trial presentations.
Three-year results of the GORE® VIABAHN® stent-graft in the superficial femoral artery in in-stent restenosis
Presented by Peter A Soukasmd
The RELINE MAX study is the first to report the 36-month long-term results of the pivotal postmarketing study of the Gore VIABAHN Endoprosthesis (Gore & Associates) for the treatment of bare-metal-in-stent restenosis (ISR) in the superficial femoral artery (SFA ).
RELINE MAX was a prospective, single-arm, international study that enrolled patients at 23 sites October 2015 to April 2018. Patients with ≥ 50% ISR or occlusion on the SFA, Rutherford disease categories 2-5, and ≥ 1 patent outflow vessel were eligible. The primary efficacy endpoint…
